{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_references_citation in Reference Text / Citation (approximate match)
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
US Previously Marketed
Source:
Mixed Tocopherols N.F.
(1921)
Source URL:
First marketed in 1921
Source:
Mixed Tocopherols N.F.
Source URL:
Class:
MIXTURE
Tocopherol (alpha tocopheryl nicotinate) is an ester of tocopherol and nicotinic acid. Vitamin E (Tocopherol) is sold commercially as the esterified form (alpha tocopheryl acetate, alpha tocopheryl succinate and alpha tocopheryl nicotinate). Alpha tocopheryl nicotinate has antioxidant and vasodilatory properties. It can be used as a mild warming agent, without producing the redness typical for nicotinic acid. Tocopherol (alpha tocopheryl nicotinate) has been available in Japan since 1967. Tocopherol under the brand name Juvela N is approved in Japan for the treatment of symptoms accompanying hypertension, hyperlipidemia, peripheral circulatory disturbance resulting from arteriosclerosis obliterans. Tocopherol has being shown to inhibit platelet aggregation.
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2021)
Source URL:
First approved in 2021
Source:
505G(a)(3)
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2019)
Source URL:
First approved in 2019
Source:
21 CFR 333E
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Antiseptic Solution by Grupo Salypro de Mexico, S.A. de C.V.
(2021)
Source URL:
First approved in 2016
Source:
All Day Skin Relief with Colloidal Oats by Lantern Enterprises Ltd.
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2023)
Source:
BLA761278
(2023)
Source URL:
First approved in 2023
Source:
BLA761278
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2008)
Source:
BLA125160
(2008)
Source URL:
First approved in 2008
Source:
BLA125160
Source URL:
Class:
PROTEIN
